ArticleCell death & disease2018

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.

Giuseppa Augello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.